| Summary: | Chronic myeloproliferative neoplasms (MPNs) are hematopoietic stem cell neoplasms with driver events including the <i>BCR-ABL1</i> translocation leading to a diagnosis of chronic myeloid leukemia (CML), or somatic mutations in <i>JAK2</i>, <i>CALR</i>, or MPL resulting in Philadelphia-chromosome-negative MPNs with constitutive activation of the JAK-STAT signaling pathway. In the Philadelphia-chromosome-negative MPNs, modern sequencing panels have identified a vast molecular landscape including additional mutations in genes involved in splicing, signal transduction, DNA methylation, and chromatin modification such as <i>ASXL1</i>, <i>SF3B1</i>, <i>SRSF2</i>, and <i>U2AF1</i>. These additional mutations often influence prognosis in MPNs and therefore are increasingly important for risk stratification. This review focuses on the molecular alterations within the WHO classification of MPNs and laboratory testing used for diagnosis.
|
|---|